Solid Biosciences

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc (NASDAQ: SLDB) reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001.  SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy for Duchenne muscular dystrophy (DMD).

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) -

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options

Solid Biosciences (SLDB) stock is rising higher today as investors prepare for an update from the company later this week. The post SLDB Stock Alert: Dear Solid Biosciences Investors, Mark Your Calendar for Sept.

SLDB Stock Alert: Dear Solid Biosciences Investors, Mark Your Calendar for Sept. 23!

The stock price of Solid Biosciences Inc (NASDAQ: SLDB) increased by over 14% during intraday trading today. This is why it happened.

SLDB Stock: Why It Significantly Increased Today

Shareholders are expecting to finally get good news.

Why Shares of Solid Biosciences Are Jumping Today

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress -

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

MeiraGTx Holdings plc

uniQure

Sarepta Therapeutics

Voyager Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

- Chief Operating Officer to discuss company's advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development -

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Finance, Michael Inbar. The grant was approved by a majority of the independent directors of the Company on July 27, 2021 as an inducement material to Mr. Inbar entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior Vice President, Finance, effective August 16, 2021.

Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 -

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici. The grant was approved by a majority of the independent directors of the Company on June 16, 2021 as an inducement material to Dr. Dreghici entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

-Additional expertise expected to support attainment of key corporate goals-

Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman Barilero. The grant was approved by a majority of the independent directors of the Company on May 5, 2021 as an inducement material to Dr. Barilero entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer

CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1, 2021.

Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences:

Solid Biosciences to Present at Upcoming Scientific Conferences

Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call Transcript

The stock price of Solid Biosciences Inc (NASDAQ: SLDB) decreased by over 20% during intraday trading. This is why it happened.

Solid Biosciences (SLDB) Stock: Over 20% Decrease Explanation

- Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -

Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results

CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louise Perry, Head of Technical Operations, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 10:30 am ET.

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

Frequency Therapeutics

Scholar Rock Holding Corp

These drugmaker stocks may have been hammered down to bargain-bin prices.

3 Beaten-Down Biotech Stocks: Can They Recover?

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled “The more we learn the less we know about DMD—From micro-dystrophin, to morpholinos, and small molecules” will be held on Thursday, April 1, 2021 from 9:00 a.m. - 9:50 a.m. Eastern Time.

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Solid Biosciences (SLDB) Ahead of Earnings?

Dyne Therapeutics

Pfizer

PTC Therapeutics

Avidity Biosciences

Vertex Pharmaceuticals

Edgewise Therapeutics has filed to raise $150 million in an IPO.

News for Solid Biosciences Stock (SLDB)